银杏酮酯滴丸联合替罗非班在急性冠脉综合征患者中的应用  

Application of Ginkgo Ketone Ester Drops Combined with Tirofiban in Patients with Acute Coronary Syndrome

作　　者：王宏刚[1] WANG Hong-Gang(Department of Cardiology,Fuxin City Hospital ofLiaoning Province,Fuxin 123000,China)

机构地区：[1]辽宁省阜新市中心医院心内科,辽宁阜新123000

出　　处：《中国药物经济学》2020年第8期62-65,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨银杏酮酯滴丸联合替罗非班治疗急性冠脉综合征患者的临床效果。方法按照随机数字表法将2016年5月至2019年2月于辽宁省阜新市中心医院接受治疗的200例急性冠脉综合征患者分为对照组与观察组,每组100例。两组患者均进行常规治疗,在此基础上给予对照组患者替罗非班进行治疗,在对照组基础上观察组患者给予银杏酮酯滴丸治疗。比较两组治疗前后肌酸激酶同工酶(CK-MB)、肌钙蛋白I(cTnI)、最大血小板聚集率(MPA)水平及治疗后不良心血管事件、不良反应发生率。结果治疗前,观察组CK-MB、cTnI、MPA水平与对照组比较,差异无统计学意义(P>0.05);治疗后,观察组CK-MB、cTnI、MPA水平低于对照组,差异有统计学意义(P<0.05);治疗后随访6个月,观察组不良心血管事件发生率为2.00%,低于对照组的12.00%,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论银杏酮酯滴丸联合替罗非班治疗急性冠脉综合征可有效改善患者CK-MB、cTnI、MPA水平,降低不良心血管事件发生率,且安全性较高。Objective To explore the effect of ginkgo ketone ester injection combined with tirofiban on patients with acute coronary syndromes.Methods According to the random number table method,a total of 200 patients with acute coronary syndrome who were treated in Fuxin City Hospital of Liaoning Province from May 2016 to February 2019 were divided into a control group and an observation group,with 100 cases in each group.The patients in both groups were given routine treatment.On this basis,the patients in the control group were given tigrello for treatment while patients in the observation group was treated with ginkgo ketone ester injection on the basis of the control group.We compared the levels of creatine kinase isoenzyme(CK-MB),troponin I(cTnI),maximum platelet aggregation rate(MPA)and the incidence of adverse cardiovascular events and adverse reactions after treatment between the two groups before and after treatment.Results There was no significant difference between CK-MB,cTnI and MPA in the observation group before treatment(P>0.05),CK-MB,cTnI and MPA in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05);follow-up for 6 months after treatment,the incidence of adverse cardiovascular events in the observation group was 2.00%,which was lower than 12.00%in the control group,and the difference was statistically significant(P<0.05);the incidence of adverse reactions between the two groups was not statistically different(P>0.05).Conclusion Ginkgo ketone ester injection combined with tirofiban in the treatment in patients with acute coronary syndrome can effectively improve their CK-MB、c Tn I、MPA levels,and reduce the incidence of adverse cardiovascular events,with better safety.

关 键 词：急性冠脉综合征 银杏酮酯滴丸 替罗非班 

分 类 号：R541.4[医药卫生—心血管疾病] R286[医药卫生—内科学]